These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21645609)

  • 1. In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma.
    Martinotti S; Ranzato E; Burlando B
    Toxicol In Vitro; 2011 Dec; 25(8):1568-74. PubMed ID: 21645609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of ascorbate/epigallocatechin-3-gallate/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells.
    Martinotti S; Ranzato E; Parodi M; Vitale M; Burlando B
    Toxicol Appl Pharmacol; 2014 Jan; 274(1):35-41. PubMed ID: 24200995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
    Volta V; Ranzato E; Martinotti S; Gallo S; Russo MV; Mutti L; Biffo S; Burlando B
    PLoS One; 2013; 8(3):e58051. PubMed ID: 23526965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel opening.
    Ranzato E; Martinotti S; Magnelli V; Murer B; Biffo S; Mutti L; Burlando B
    J Cell Mol Med; 2012 Nov; 16(11):2667-78. PubMed ID: 22564432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells.
    Valenti D; de Bari L; Manente GA; Rossi L; Mutti L; Moro L; Vacca RA
    Biochim Biophys Acta; 2013 Dec; 1832(12):2085-96. PubMed ID: 23911347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
    Bertino P; Piccardi F; Porta C; Favoni R; Cilli M; Mutti L; Gaudino G
    Clin Cancer Res; 2008 Jan; 14(2):541-8. PubMed ID: 18223230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma.
    Shen R; Li J; Ye D; Wang Q; Fei J
    Acta Biochim Biophys Sin (Shanghai); 2016 Oct; 48(10):894-901. PubMed ID: 27590062
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Guazzelli A; Meysami P; Bakker E; Demonacos C; Giordano A; Krstic-Demonacos M; Mutti L
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
    Zanellato I; Boidi CD; Lingua G; Betta PG; Orecchia S; Monti E; Osella D
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):265-73. PubMed ID: 20369238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism.
    Ranzato E; Biffo S; Burlando B
    Am J Respir Cell Mol Biol; 2011 Jan; 44(1):108-17. PubMed ID: 20203294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
    Cameron RB; Hou D
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):496-504. PubMed ID: 23174177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
    Sei S; Mussio JK; Yang QE; Nagashima K; Parchment RE; Coffey MC; Shoemaker RH; Tomaszewski JE
    Mol Cancer; 2009 Jul; 8():47. PubMed ID: 19594950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
    Szulkin A; Nilsonne G; Mundt F; Wasik AM; Souri P; Hjerpe A; Dobra K
    PLoS One; 2013; 8(6):e65903. PubMed ID: 23840376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
    Vázquez R; Licandro SA; Astorgues-Xerri L; Lettera E; Panini N; Romano M; Erba E; Ubezio P; Bello E; Libener R; Orecchia S; Grosso F; Riveiro ME; Cvitkovic E; Bekradda M; D'Incalci M; Frapolli R
    Int J Cancer; 2017 Jan; 140(1):197-207. PubMed ID: 27594045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
    Shen X; Wang J; Deng B; Chen S; John C; Zhao Z; Sinha N; Haag J; Sun W; Kong W; Spasojevic I; Batinic-Haberle I; Secord AA; Zhou C; Bae-Jump VL
    Gynecol Oncol; 2024 Apr; 183():93-102. PubMed ID: 38555710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.
    Tallón de Lara P; Cecconi V; Hiltbrunner S; Yagita H; Friess M; Bode B; Opitz I; Vrugt B; Weder W; Stolzmann P; Felley-Bosco E; Stahel RA; Tischler V; Britschgi C; Soldini D; van den Broek M; Curioni-Fontecedro A
    Clin Cancer Res; 2018 Dec; 24(24):6345-6354. PubMed ID: 30154226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
    Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
    Makiyama A; Qin B; Uchino K; Shibata Y; Arita S; Isobe T; Hirano G; Kusaba H; Baba E; Akashi K; Nakano S
    Anticancer Drugs; 2009 Feb; 20(2):123-30. PubMed ID: 19209029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
    Edelman MJ; Quam H; Mullins B
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):141-4. PubMed ID: 11561780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Guechev A; Smid K; Loves WJ; Vermorken JB; Postmus PE; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):407-15. PubMed ID: 9933029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.